Table 1.
Demographic and pathological tumour characteristics of 1072 patients without 30-day mortality constituting the basis for survival calculations
| Demographics and pathological tumor characteristics (n = 1108) | |||||
|---|---|---|---|---|---|
| Epidemiology | |||||
| Patients | Time period I | Time period II | Time period III | p-value | All time periods |
| (1986–1994) | (1995–2003) | (2004 – 2013) | |||
| n = 363 (32.8%) | n = 349 (31.5%) | n = 396 (35.7%) | n = 1108 (100%) | ||
| 30d mortality | 8 | 14 | 14 | 0.37 | 36 |
| (2.2%) | (4.0%) | (3.5%) | (3.2%) | ||
| Patients w/o 30d-mortality | n = 355 | n = 335 | n = 382 | n = 1072 | |
| (33.1%) | (31.2%) | (35.6%) | (100%) | ||
| Median age (y) | 63.81 | 65.56 | 65.70 y | 0.13* | 65.05 y |
| (19.59 -91.24) | (34.33 -91.58) | (21.78 - 93.91) | (19.59 - 93.91) | ||
| Gender m/f | 224/131 (63.1/36.9%) | 216/119 (64.5/35.5%) | 243/139 (63.6/36.4%) | 0.93 | 683/389 (63.7/36.3%) |
| Tumor characteristics/staging of patients w/o 30d mortality (n = 1072) | |||||
| UICC stage I | 82 (23.1%) | 82 (24.5%) | 103 (27.0%) | 0.47 | 267 (24.9%) |
| UICC stage II | 83 (23.4%) | 102 (30.4%) | 100 (26.2%) | 0.11 | 285 (26.6%) |
| UICC stage III | 63 (17.7%) | 42 (12.5%) | 57 (14.9%) | 0.16 | 162 (15.1%) |
| UICC stage IV | 111 (31.3%) | 105 (31.3%) | 114 (29.8%) | 0.88 | 330 (30.8%) |
| UICC stage X | 16 (4.5%) | 4 (1.2%) | 8 (2.1%) | 0.02 | 28 (2.6%) |
| T1/Tis | 61 (17.2%) | 50 (14.9%) | 61 (16.0%) | 0.72 | 172 (16.0%) |
| T2 | 107 (30.1%) | 141 (42.1%) | 89 (23.3%) | <0.001 | 337 (31.4%) |
| T3 | 89 (25.1%) | 79 (23.6%) | 124 (32.5%) | 0.015 | 292 (27.2%) |
| T4 | 76 (21.4%) | 58 (17.3%) | 92 (24.1%) | 0.084 | 226 (21.1%) |
| Tx | 22 (6.2%) | 7 (2.1%) | 16 (4.2%) | 0.027 | 45 (4.2%) |
| N0 | 95 (6.8%) | 99 (29.6%) | 137 (35.9%) | 0.023 | 331 (30.9%) |
| N1 | 55 (15.5%) | 98 (29.3%) | 132 (34.6%) | <0.001 | 285 (26.6%) |
| ≥ N2 | 168 (47.3%) | 119 (35.5%) | 82 (21.5%) | <0.001 | 369 (34.4%) |
| Nx | 37 (10.4%) | 19 (5.7%) | 31 (8.1%) | 0.074 | 87 (8.1%) |
| G1 | 11 (3.1%) | 5 (1.5%) | 7 (1.8%) | 0.302 | 23 (2.1%) |
| G2 | 79 (22.3%) | 99 (29.6%) | 99 (25.9%) | 0.091 | 277 (25.8%) |
| G3 | 142 (40.0%) | 209 (62.4%) | 239 (62.6%) | <0.001 | 590 (55.0%) |
| G4 | 7 (2.0%) | 1 (0.3%) | 8 (2.1%) | 0.093 | 16 (1.5%) |
| Gx | 116 (32.7%) | 21 (6.3%) | 29 (7.6%) | <0.001 | 166 (15.5%) |
| Signet Ring Cell | 13 | 8 | 7 | 0.284 | 28 |
| 3,7% | 2,4% | 1,8% | 2,6% | ||
| synPC | 35 (9.9%) | 49 (14.6%) | 74 (19.4%) | 0.001 | 158 (14.7%) |
| synPC (isol.) | 11 (3.1%) | 30 (9.0%) | 45 (11.8%) | <0.001 | 86 (7.9%) |
| synM+ (*) | 99 (27.9%) | 75 (22.4%) | 68 (17.8%) | 0.005 | 242 (22.6%) |
| synFM (isol.) | 75 (21.1%) | 56 (16.7%) | 39 (10.2%) | <0.001 | 170 (15.9%) |
| synPC/synM+ (*) | 24 (6.8%) | 19 (5.7%) | 29 (7.6%) | 0.591 | 72 (6.7%) |
The characteristics are stratified for the three time period of treatment (*Kruskal-Wallis-Test)